Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,089 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing.
Prasanna G, Ferrara L, Adams C, Ehara T, Li B, Yang L, Xiang C, Ng CTH, Kim S, Towler C, Topley T, McAllister C, Ghosh M, Newton R, Stacy R, Rice DS, Mogi M. Prasanna G, et al. Among authors: newton r. Invest Ophthalmol Vis Sci. 2018 Apr 1;59(5):1704-1716. doi: 10.1167/iovs.18-23772. Invest Ophthalmol Vis Sci. 2018. PMID: 29610853
A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma.
Stacy R, Huttner K, Watts J, Peace J, Wirta D, Walters T, Sall K, Seaman J, Ni X, Prasanna G, Mogi M, Adams C, Yan JH, Wald M, He Y, Newton R, Kolega R, Grosskreutz C. Stacy R, et al. Among authors: newton r. Am J Ophthalmol. 2018 Aug;192:113-123. doi: 10.1016/j.ajo.2018.05.015. Epub 2018 May 24. Am J Ophthalmol. 2018. PMID: 29802818 Clinical Trial.
Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.
Lorthiois E, Anderson K, Vulpetti A, Rogel O, Cumin F, Ostermann N, Steinbacher S, Mac Sweeney A, Delgado O, Liao SM, Randl S, Rüdisser S, Dussauge S, Fettis K, Kieffer L, de Erkenez A, Yang L, Hartwieg C, Argikar UA, La Bonte LR, Newton R, Kansara V, Flohr S, Hommel U, Jaffee B, Maibaum J. Lorthiois E, et al. Among authors: newton r. J Med Chem. 2017 Jul 13;60(13):5717-5735. doi: 10.1021/acs.jmedchem.7b00425. Epub 2017 Jun 30. J Med Chem. 2017. PMID: 28621538
Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics.
de Zafra CLZ, Sasseville VG, Matsumoto S, Freichel C, Milton M, MacLachlan TK, Farman C, Raymond I, Gupta S, Newton R, Atzpodien EA, Thackaberry EA. de Zafra CLZ, et al. Among authors: newton r. Regul Toxicol Pharmacol. 2017 Jun;86:221-230. doi: 10.1016/j.yrtph.2017.03.013. Epub 2017 Mar 16. Regul Toxicol Pharmacol. 2017. PMID: 28322894
Corrigendum to "Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics" [Regul. Toxicol. Pharmacol. (2017) 221-230].
de Zafra CLZ, Sasseville VG, Matsumoto S, Freichel C, Milton M, MacLachlan TK, Farman C, Raymond I, Gupta S, Newton R, Atzpodien EA, Thackaberry EA. de Zafra CLZ, et al. Among authors: newton r. Regul Toxicol Pharmacol. 2017 Aug;88:364. doi: 10.1016/j.yrtph.2017.04.006. Epub 2017 Apr 18. Regul Toxicol Pharmacol. 2017. PMID: 28431771 No abstract available.
Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses.
Briercheck EL, Ravishankar S, Ahmed EH, Carias Alvarado CC, Barrios Menéndez JC, Silva O, Solórzano-Ortiz E, Siliezar Tala MM, Stevenson PA, Xu Y, Wohns AW, Enriquez-Vera D, Barrionuevo C, Yu SC, Freud AG, Weigel C, Oakes CC, Weinstock DM, Klimaszewski HL, Ngankeu A, Mutalima N, Samayoa-Reyes G, Newton R Prof, Rochford R, Valvert F, Natkunam Y, Shustov A, Baiocchi RA, Warren EH. Briercheck EL, et al. Among authors: newton r prof. Blood Adv. 2024 May 30:bloodadvances.2023012461. doi: 10.1182/bloodadvances.2023012461. Online ahead of print. Blood Adv. 2024. PMID: 38815238
Peer support for people living with hepatitis B virus-A foundation for treatment expansion.
Downs LO, Kabagambe K, Williams S, Waddilove E, Delphin M, Lumley SF, Ndungutse R, Kimono B, Newton R, Ko J, Martyn E, Carter J, Kemper A, Monteiro F, O'Regan S, Surey J, Sultan B, Story A, MacDonald D, Tu T, Seeley J, Dusheiko G, Maponga T, Andersson MI, Spearman CW, Tucker JD, Cohen C, Wang S, Adda D, Freeland C, Halford R, Jack K, Ghosh I, Elsharkawy AM, Matthews PC, Flanagan S. Downs LO, et al. Among authors: newton r. J Viral Hepat. 2024 May 26. doi: 10.1111/jvh.13952. Online ahead of print. J Viral Hepat. 2024. PMID: 38798022 Review.
Emerging Variants of Canine Enteric Coronavirus Associated with Outbreaks of Gastroenteric Disease.
Cunningham-Oakes E, Pilgrim J, Darby AC, Appleton C, Jewell C, Rowlingson B, Cuartero CT, Newton R, Sánchez-Vizcaíno F, Fins IS, Brant B, Smith S, Penrice-Randal R, Clegg SR, Roberts APE, Millson SH, Pinchbeck GL, Noble PM, Radford AD. Cunningham-Oakes E, et al. Among authors: newton r. Emerg Infect Dis. 2024 Jun;30(6):1240-1244. doi: 10.3201/eid3006.231184. Emerg Infect Dis. 2024. PMID: 38782018 Free PMC article.
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC, Logue J, Payne H, Forcat S, Goldstein C, Murphy C, Anderson J, Barkati M, Bottomley DM, Branagan J, Choudhury A, Chung PWM, Cogley L, Goh CL, Hoskin P, Khoo V, Malone SC, Masters L, Morris SL, Nabid A, Ong AD, Raman R, Tarver KL, Tree AC, Worlding J, Wylie JP, Zarkar AM, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 Jun 1;403(10442):2405-2415. doi: 10.1016/S0140-6736(24)00548-8. Epub 2024 May 16. Lancet. 2024. PMID: 38763154 Free article. Clinical Trial.
2,089 results